Global Hypercalcemia Treatment Market 2017-2021

  • ID: 4211617
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • DiaSorin
  • Fujirebio
  • Kyowa Hakko Kirin
  • Merck
  • MORE
Hypercalcemia is a condition in which the calcium level in the blood is above normal. Too much calcium in the blood can weaken the bones, create stones in the kidneys, and interfere with the functioning of the heart and the brain. Hypercalcemia refers to the condition where too much calcium enters the extracellular fluid or when there is insufficient calcium excretion from the kidneys. The cases of hypercalcemia are mainly caused by malignancy or hyperparathyroidism. Hypercalcemia is an outcome of overactive parathyroid glands. These four tiny glands are located near thyroid gland and each of them are about the size of a rice grain.

The analysts forecast the global hypercalcemia treatment market to grow at a CAGR of 5.44% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global hypercalcemia treatment market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Hypercalcemia Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AbbVie
- Amgen
- Merck
- Novartis
- OPKO Health

Other prominent vendors
- DiaSorin
- Rockwell Medical
- Kyowa Hakko Kirin
- Fujirebio

Market drivers
- Expanding label indications.
- For a full, detailed list, view the full report

Market challenges
- Severe threat of damage to nervous system.
- For a full, detailed list, view the full report

Market trends
- Growing focus on emerging economies.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • DiaSorin
  • Fujirebio
  • Kyowa Hakko Kirin
  • Merck
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: An overview of Hypercalcemia

PART 06: Pipeline Analysis

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by product type
  • Bisphosphonates
  • Glucocorticoids
  • Calcimimetic agents
  • Others
PART 09: Market segmentation by geography
  • Hypercalcemia treatment market in Americas
  • Hypercalcemia treatment market in EMEA
  • Hypercalcemia treatment market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments
PART 12: Market trends
  • Combination therapy
  • Increase in outsourcing
  • Growing focus on emerging economies
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • AbbVie
  • Amgen
  • Merck
  • Novartis
  • OPKO Health
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits

Exhibit 01: Body parts affected by high calcium
Exhibit 02: Pipeline landscape
Exhibit 03: Global hypercalcemia treatment market snapshot
Exhibit 04: Global hypercalcemia treatment market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis in global hypercalcemia treatment market
Exhibit 06: Five forces analysis
Exhibit 07: Market segmentation by product type 2016
Exhibit 08: Bisphosphonates segment 2016-2021 ($ millions)
Exhibit 09: Glucocorticoids segment 2016-2021 ($ millions)
Exhibit 10: Calcimimetic agents segment 2016-2021 ($ millions)
Exhibit 11: Global hypercalcemia treatment market by geography 2016 and 2021
Exhibit 12: Global hypercalcemia treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 13: Market scenario in Americas
Exhibit 14: Hypercalcemia treatment market in Americas ($ millions)
Exhibit 15: Market scenario in EMEA
Exhibit 16: Hypercalcemia treatment market in EMEA ($ millions)
Exhibit 17: Market scenario in APAC
Exhibit 18: Hypercalcemia treatment market in APAC ($ millions)
Exhibit 19: Key approvals
Exhibit 20: Key factors driving the market growth
Exhibit 21: Impact of drivers
Exhibit 22: Impact of serum calcium concentration
Exhibit 23: Impact of challenges
Exhibit 24: Competitive structure analysis of global hypercalcemia treatment market 2016
Exhibit 25: Competitive analysis of global hypercalcemia market
Exhibit 26: AbbVie: Key highlights
Exhibit 27: AbbVie: Strength assessment
Exhibit 28: AbbVie: Strategy assessment
Exhibit 29: AbbVie: Opportunity assessment
Exhibit 30: Amgen: Key highlights
Exhibit 31: Amgen: Strength assessment
Exhibit 32: Amgen: Strategy assessment
Exhibit 33: Amgen: Opportunity assessment
Exhibit 34: Merck: Key highlights
Exhibit 35: Merck: Strength assessment
Exhibit 36: Merck: Strategy assessment
Exhibit 37: Merck: Opportunity assessment
Exhibit 38: Novartis: Strength assessment
Exhibit 39: Novartis: Strategy assessment
Exhibit 40: Novartis: Opportunity assessment
Exhibit 41: OPKO Health: Key highlights
Exhibit 42: OPKO Health: Strength assessment
Exhibit 43: OPKO Health: Strategy assessment
Exhibit 44: OPKO Health: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • DiaSorin
  • Fujirebio
  • Kyowa Hakko Kirin
  • Merck
  • MORE
New Report Released: - Global Hypercalcemia Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global hypercalcemia treatment market: AbbVie, Amgen, Merck, Novartis, and OPKO Health.

Other Prominent Vendors in the market are: DiaSorin, Rockwell Medical, Kyowa Hakko Kirin, and Fujirebio.

Commenting on the report, an analyst from the research team said: “One trend in market is combination therapy. Although the preference for hypercalcemia drugs in developed countries is increasing, the use of hypercalcemia drugs in combination with other therapies will help maintain the adoption rates. For instance, researchers have evaluated the use of combination drugs, which include pamidronate and calcitonin. This should increase the demand for hypercalcemia drugs in developed countries.”

According to the report, one driver in market is expanding label indications. As the market is dominated by generic products, label extensions will provide more opportunities for revenue generation. This is expected to propel the market growth substantially. Vendors are also increasingly focusing on developing drugs for segments such as parathyroidism and CKD. For instance, in 2016, OPKO Health received approval from the US FDA for Rayaldee (extended-release capsules) for the treatment of SHPT in adults with CKD and serum total 25-hydroxyvitamin D. Also, in November 2016, Amgen received approval from the EC for Parsabiv (etelcalcetide) to treat SHPT in adults with CKD on hemodialysis. In September 2015, Rockwell Medical Launched Calcitriol in the US for the treatment of iron replacement, SHPT, and hemodialysis. The increase in label indications will expand the scope of hypercalcemia, thereby driving the market growth.

Further, the report states that one challenges in market is patent expiries of major drugs. Patent expiries result in the loss of an exclusive market for a drug, leading to a rapid decline in its sales. The introduction of low-cost drugs is likely to increase the competition in the market. The market has experienced the limited availability of branded products due to the patent expiry of major drugs such as Amgen’s Sensipar, which lost its patent in 2016. Similarly, AbbVie’s ZEMPLAR (paricalcitol) lost its patent in 2015, and Sanofi-Aventis US’s Hectorol (doxercalciferol), which was an intravenous for the treatment of SHPT, had lost its patent in 2014. Thus, the patent expiries of major drugs result in the decline of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AbbVie
  • Amgen
  • Merck
  • Novartis
  • OPKO Health
  • DiaSorin
  • Rockwell Medical
  • Kyowa Hakko Kirin
  • Fujirebio
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll